Melbourne Australia;  - Starpharma Holdings Ltd (ASX: SPL; OTCQX: SPHRY) today announced a new senior appointment to its experienced and successful business development team.

Dr Tony Eglezos has been appointed to the position of VP of Business Development working alongside Starpharma’s existing VP of Business Development Dr Paul Barrett to expand the resources available for negotiating partnering arrangements.

Tony has worked for more than 20 years in the pharmaceutical industry in Australia, the US and Europe for companies including CSL, Amgen, Abbott Labs and Abbott Australia.

Most recently he was Director Commercial Operations, Pharmaceuticals and In-Licensing at bioCSL and, prior to that, Senior Director Business Development and Licensing at CSL. During his career he has contributed to the commercialisation of novel pharmaceuticals in urology, neurology, nephrology, cardiology, dermatology, pain and critical care.

“Tony comes to Starpharma with an impressive background in product commercialisation and licensing across a wide range of technologies and therapeutic areas and so his skills and experience are well suited to the progression of our broad dendrimer-based product portfolio,” said Starpharma chief executive Dr Jackie Fairley.

“Tony joins us at an important time and will provide valuable additional resource and commercial expertise as VivaGel^® enters the final stage of development in bacterial vaginosis, with discussions underway with a number of interested parties.”

During his 7 years in business development with CSL, Tony’s responsibilities included acquisitions and due-diligence, commercialisation of in-licensed pharmaceutical products and out-licensing of IP for partnered development for the global R&D group.

Tony has a PhD in Immunology from the University of Melbourne and an MBA from the University of Technology Sydney. He will commence at Starpharma in August.

Download ASX Announcement: Starpharma appoints Business Development executive (pdf file, 105kb)